FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3016222021> ?p ?o ?g. }

• W3016222021 endingPage "1446" @default.
• W3016222021 startingPage "1435" @default.
• W3016222021 abstract "Objective To evaluate fenebrutinib, an oral and highly selective noncovalent inhibitor of Bruton's tyrosine kinase ( BTK ), in patients with active rheumatoid arthritis ( RA ). Methods Patients with RA and an inadequate response to methotrexate ( MTX ) (cohort 1; n = 480) were randomized to receive fenebrutinib (50 mg once daily, 150 mg once daily, or 200 mg twice daily), adalimumab (40 mg every other week), or placebo. Patients with RA and an inadequate response to tumor necrosis factor inhibitors (cohort 2; n = 98) received fenebrutinib (200 mg twice daily) or placebo. Both cohorts continued MTX therapy. Results In cohort 1, the percentages of patients in whom American College of Rheumatology 50% improvement criteria ( ACR 50) was achieved at week 12 were similar in the fenebrutinib 50 mg once daily and placebo groups, and were higher in the fenebrutinib 150 mg once daily group (28%) and 200 mg twice daily group (35%) than in the placebo group (15%) ( P = 0.016 and P = 0.0003, respectively). Fenebrutinib 200 mg twice daily and adalimumab (36%) were comparable ( P = 0.81). In cohort 2, ACR 50 was achieved in more patients receiving fenebrutinib 200 mg twice daily (25%) than placebo (12%) ( P = 0.072). The most common adverse events in the fenebrutinib groups included nausea, headache, anemia, and upper respiratory tract infections. Fenebrutinib had significant effects on myeloid and B cell biomarkers ( CCL 4 and rheumatoid factor). Fenebrutinib and adalimumab caused overlapping as well as distinct changes in B cell and myeloid biomarkers. Conclusion Fenebrutinib demonstrates efficacy comparable to adalimumab in patients with an inadequate response to MTX , and safety consistent with existing immunomodulatory therapies for RA . These data support targeting both B and myeloid cells via this novel mechanism for potential efficacy in the treatment of RA ." @default.
• W3016222021 created "2020-04-17" @default.
• W3016222021 creator A5000308788 @default.
• W3016222021 creator A5000317186 @default.
• W3016222021 creator A5000635386 @default.
• W3016222021 creator A5000651169 @default.
• W3016222021 creator A5000755023 @default.
• W3016222021 creator A5000777758 @default.
• W3016222021 creator A5000779664 @default.
• W3016222021 creator A5001667792 @default.
• W3016222021 creator A5003819213 @default.
• W3016222021 creator A5004043747 @default.
• W3016222021 creator A5004431830 @default.
• W3016222021 creator A5005632142 @default.
• W3016222021 creator A5005749362 @default.
• W3016222021 creator A5005753288 @default.
• W3016222021 creator A5005897527 @default.
• W3016222021 creator A5006411548 @default.
• W3016222021 creator A5006996011 @default.
• W3016222021 creator A5007191897 @default.
• W3016222021 creator A5007964814 @default.
• W3016222021 creator A5008119494 @default.
• W3016222021 creator A5008176155 @default.
• W3016222021 creator A5008312438 @default.
• W3016222021 creator A5010300728 @default.
• W3016222021 creator A5010607831 @default.
• W3016222021 creator A5011725686 @default.
• W3016222021 creator A5012183727 @default.
• W3016222021 creator A5013539912 @default.
• W3016222021 creator A5013886561 @default.
• W3016222021 creator A5014946592 @default.
• W3016222021 creator A5015146629 @default.
• W3016222021 creator A5015262501 @default.
• W3016222021 creator A5015570314 @default.
• W3016222021 creator A5015922677 @default.
• W3016222021 creator A5015980792 @default.
• W3016222021 creator A5017740190 @default.
• W3016222021 creator A5018132469 @default.
• W3016222021 creator A5018480588 @default.
• W3016222021 creator A5018933819 @default.
• W3016222021 creator A5019856399 @default.
• W3016222021 creator A5019944698 @default.
• W3016222021 creator A5020415746 @default.
• W3016222021 creator A5020565226 @default.
• W3016222021 creator A5021467102 @default.
• W3016222021 creator A5021501630 @default.
• W3016222021 creator A5021513291 @default.
• W3016222021 creator A5022501068 @default.
• W3016222021 creator A5023473892 @default.
• W3016222021 creator A5023552165 @default.
• W3016222021 creator A5023943479 @default.
• W3016222021 creator A5024436369 @default.
• W3016222021 creator A5024878483 @default.
• W3016222021 creator A5024934467 @default.
• W3016222021 creator A5025024227 @default.
• W3016222021 creator A5026300891 @default.
• W3016222021 creator A5026654916 @default.
• W3016222021 creator A5026684685 @default.
• W3016222021 creator A5028400410 @default.
• W3016222021 creator A5028863296 @default.
• W3016222021 creator A5028900078 @default.
• W3016222021 creator A5028916428 @default.
• W3016222021 creator A5029221041 @default.
• W3016222021 creator A5029869341 @default.
• W3016222021 creator A5030487188 @default.
• W3016222021 creator A5030599616 @default.
• W3016222021 creator A5031549876 @default.
• W3016222021 creator A5032707830 @default.
• W3016222021 creator A5032940273 @default.
• W3016222021 creator A5033614746 @default.
• W3016222021 creator A5035577773 @default.
• W3016222021 creator A5036380035 @default.
• W3016222021 creator A5036400874 @default.
• W3016222021 creator A5036562198 @default.
• W3016222021 creator A5036599777 @default.
• W3016222021 creator A5036792186 @default.
• W3016222021 creator A5038610362 @default.
• W3016222021 creator A5038952228 @default.
• W3016222021 creator A5039787600 @default.
• W3016222021 creator A5039796536 @default.
• W3016222021 creator A5039980536 @default.
• W3016222021 creator A5040632806 @default.
• W3016222021 creator A5040971680 @default.
• W3016222021 creator A5041565363 @default.
• W3016222021 creator A5041748817 @default.
• W3016222021 creator A5041778235 @default.
• W3016222021 creator A5042068235 @default.
• W3016222021 creator A5042126419 @default.
• W3016222021 creator A5042601081 @default.
• W3016222021 creator A5043714352 @default.
• W3016222021 creator A5044668593 @default.
• W3016222021 creator A5044701477 @default.
• W3016222021 creator A5044877399 @default.
• W3016222021 creator A5046561316 @default.
• W3016222021 creator A5046937510 @default.
• W3016222021 creator A5048750280 @default.
• W3016222021 creator A5048939802 @default.
• W3016222021 creator A5048988940 @default.

• next